Editas Medicine, Inc.(EDIT)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
EDIT | 396.2 M | - | 232.30% | -157.32% | -$0.68 | -118.82% | 0.15x | 0.00% | $4.28 | $1.66 |
ZURA | 383.3 M | - | - | 0.00% | -$1.12 | -51.01% | - | 0.00% | $7.44 | $3.15 |
CYDY | 367.4 M | - | - | 0.00% | -$0.03 | - | - | 0.00% | $0.40 | $0.18 |
EBS | 322.5 M | - | 66.30% | -22.96% | -$3.40 | -40.29% | 1.72x | 0.00% | $14.06 | $4.36 |
XFOR | 299.4 M | 151.00x | 346.30% | 0.00% | $0.02 | -113.08% | 0.50x | 0.00% | $4.83 | $2.43 |
Peer Valuation & Performance Analysis
Peer group analysis for Editas Medicine, Inc. (EDIT) compared to its primary competitors (including ZURA, CYDY, EBS) reveals distinct metrics. EDIT trades at a valuation discount relative to its competitors, with a P/E ratio of -3.8x versus the peer average of 34.3x (representing a 111% discount). This discount might represent an undervalued entry opportunity or reflect specific risk factors the market is discounting. In terms of growth, EDIT's revenue growth of 232.3% exceeds the peer average of 206.3%, highlighting its competitive strength and market share gains. Additionally, its net margin of -157.3% is below the peer average of -5.7%, suggesting higher operational costs or lower pricing power relative to peers.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• EDIT ranks #0 in P/E ratio, #2 in revenue growth, and #5 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-20 | $2.40 | $2.67 | $2.35 | $2.58 | 2,245,766 | +6.61% |
| 2026-10-19 | $2.38 | $2.43 | $2.27 | $2.42 | 2,009,900 | +2.98% |
| 2026-10-16 | $2.44 | $2.47 | $2.33 | $2.35 | 1,551,300 | -3.69% |
| 2026-10-15 | $2.26 | $2.46 | $2.25 | $2.44 | 1,858,600 | +7.49% |
| 2026-10-14 | $2.44 | $2.48 | $2.25 | $2.27 | 2,827,200 | -7.16% |
| 2026-10-13 | $2.73 | $2.73 | $2.44 | $2.44 | 2,449,700 | -11.09% |
| 2026-10-12 | $2.90 | $2.91 | $2.73 | $2.75 | 1,296,400 | -5.17% |
| 2026-10-09 | $2.85 | $2.97 | $2.71 | $2.90 | 3,087,100 | +2.11% |
| 2026-10-08 | $2.79 | $2.94 | $2.69 | $2.84 | 6,067,000 | +3.27% |
| 2026-10-07 | $2.71 | $2.85 | $2.66 | $2.75 | 2,264,700 | +0.73% |
| 2026-10-06 | $2.85 | $2.90 | $2.71 | $2.73 | 2,967,500 | -2.15% |
| 2026-10-05 | $2.62 | $2.81 | $2.56 | $2.79 | 3,012,000 | +6.49% |
| 2026-10-02 | $2.57 | $2.63 | $2.51 | $2.62 | 2,162,800 | +3.97% |
| 2026-10-01 | $2.61 | $2.62 | $2.52 | $2.52 | 1,544,200 | -1.95% |
| 2026-09-30 | $2.61 | $2.72 | $2.55 | $2.57 | 1,624,500 | -0.77% |
Explore More Analysis for EDIT
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.